Corcept Therapeutics

Lawsuit filed against $CORT alleging executives made false statements about relacorilant's clinical strength and FDA approval prospects, concealing regulatory concerns.

Class action filed against $CORP alleging securities fraud over misleading statements about relacorilant clinical trials and FDA regulatory prospects.

$CORT faces securities fraud lawsuit alleging false statements about relacorilant's FDA approval status. Investors from October 2024-December 2025 can join class action with Schall Law Firm.

Corcept Therapeutics faces class action lawsuit alleging misrepresentation of relacorilant clinical trial data and FDA approval prospects. Investors from Oct 2024-Dec 2025 may seek compensation.

Rosen Law Firm files securities fraud class action against Corcept Therapeutics, alleging misrepresentation of relacorilant drug trial data. Lead plaintiff deadline: April 21, 2026.

Rosen Law Firm notifies Corcept investors about securities lawsuit alleging misrepresentation of relacorilant clinical data and concealment of FDA concerns during October 2024-December 2025.

Rosen Law Firm seeks lead plaintiffs in securities class action against Corcept Therapeutics, alleging misrepresentation of FDA communications and clinical trial data for relacorilant drug.

Rosen Law Firm notifies $CORT investors of securities class action alleging misrepresentation of clinical trial data for relacorilant drug and undisclosed FDA concerns.

Schall Law Firm seeks investors in $COPT securities class action, alleging false statements about relacorilant FDA approval prospects between October 2024 and December 2025.

Rosen Law Firm filed securities class action against Oracle, alleging materially false statements about AI infrastructure strategy and undisclosed capital expenditures. Affected investors urged to consult legal counsel before deadline.

Rosen Law Firm sues Corcept Therapeutics for allegedly making misleading statements about clinical trial data and FDA approval prospects for its relacorilant drug candidate.

Corcept Therapeutics faces securities lawsuit alleging misrepresentation of relacorilant clinical data and FDA approval prospects, while withholding known regulatory risks from investors.